title: Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus.
abstract: OBJECTIVE
  Plasma semicarbazide-sensitive amine oxidase (SSAO) is elevated in patients with type 1 and type 2 diabetes and has been implicated in the pathophysiology of diabetic late complications. The regulation of SSAO production remains unknown. We studied correlations between plasma SSAO activity and parameters associated with diabetic late complications.
  
  
  METHODS
  Plasma SSAO was measured in a well-characterised group of 287 patients with type 1 diabetes. Standard statistical methods were used to investigate correlations with clinical parameters and components of the renin-angiotensin system.
  
  
  RESULTS
  Overall, plasma SSAO was elevated, at 693+/-196 mU/l (mean+/-SD; normal controls 352+/-102 mU/l). Plasma SSAO was higher in the group with late complications or hypertension, and in patients treated with ACE-inhibitors. In univariate analysis a significant positive correlation (p<0.001, r=0.27) was found between plasma SSAO and serum ACE activity in patients untreated with ACE inhibitors or angiotensin II receptor antagonists (n=221), but plasma SSAO did not differ by ACE I/D genotype. Plasma SSAO correlated positively with duration of diabetes, HbA(1)c and plasma renin, and negatively with plasma angiotensinogen and body mass index. A multiple regression analysis including these variables resulted in serum ACE activity (p<0.001), ACE genotype (negatively, p<0.001) and HbA(1)c (p=0.023) as explaining variables.
  
  
  CONCLUSIONS
  Results suggest that a common factor is involved in the regulation of both plasma SSAO and serum ACE, which is different from the genetic determination of ACE activity.
authors.affiliation: Department of Internal Medicine, Erasmus MC, Room Bd-234, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands. f.boomsma@erasmusmc.nl
authors.forename: F
authors.initials: F
authors.lastname: Boomsma
authors.forename: U
authors.initials: U
authors.lastname: Pedersen-Bjergaard
authors.forename: B
authors.initials: B
authors.lastname: Agerholm-Larsen
authors.forename: H
authors.initials: H
authors.lastname: Hut
authors.forename: S S
authors.initials: SS
authors.lastname: Dhamrait
authors.forename: B
authors.initials: B
authors.lastname: Thorsteinsson
authors.forename: A H
authors.initials: AH
authors.lastname: van den Meiracker
mesh_terms: D006631:Amine Oxidase (Copper-Containing) / Q000097:blood*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015992:Body Mass Index; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000201:enzymology; D003925:Diabetic Angiopathies / Q000097:blood; D017719:Diabetic Foot / Q000097:blood / Q000601:surgery; D003928:Diabetic Nephropathies / Q000097:blood; D003929:Diabetic Neuropathies / Q000097:blood; D003930:Diabetic Retinopathy / Q000097:blood; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007703:Peptidyl-Dipeptidase A / Q000097:blood* / Q000235:genetics
chemical_list: D006631:Amine Oxidase (Copper-Containing); D000806:Angiotensin-Converting Enzyme Inhibitors; D006442:Glycated Hemoglobin; D007703:Peptidyl-Dipeptidase A